Your session is about to expire
← Back to Search
Pimavanserin for Autism
Study Summary
This trial tests a new drug for Autism Spectrum Disorder in participants aged 16-40. It is randomized, placebo-controlled & cross-over designed to test safety & preliminary efficacy.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 6 Patients • NCT04188392Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I tested positive for drugs but can stop using cannabis if I have a prescription.I agree to not change my current medications or treatments during the study.I am unable to follow all the study's requirements.I or someone in my family has a history of sudden death or long QT syndrome.I don't have any serious health issues that would make it unsafe for me to join the study.My diabetes is not under control or my HbA1c level is above 8%.I have tested positive for hepatitis C or HIV.I have had a seizure in the last year or am on stable medication for seizures.I am 18 or older and willing to sign the consent form.I can swallow pills with liquid.I have not had electroconvulsive therapy in the last 6 months.I am between 16 and 40 years old.I started new psychotherapy or changed my therapy intensity within the last 2 months.I can take my medication by myself or have someone who can help me.I've had a recent heart attack or stroke, or have serious heart issues.I haven't had cancer in the last 5 years, except for certain skin cancers or cervical cancer that's considered cured.I am currently taking medication for depression or psychosis.I have been diagnosed with Autism Spectrum Disorder by a licensed professional.
- Group 1: Pimavanserin tartrate
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research endeavor allow for participants who are older than 25?
"The parameters for enrollment dictate that participants within this trial must be between 16 and 40 years old. Additionally, there are 258 trials available to minors and 47 studies open to senior citizens."
Are there any remaining vacancies for participants in this clinical experiment?
"At the time of writing, this clinical trial is not actively recruiting patients. The initial posting was on August 15th 2023 and the most recent edit was 2 days ago; however, 304 other medical trials currently have open recruitment programs."
Would it be possible for me to join this clinical research project?
"Eligibility for this research is limited to those 16-40 years old with a diagnosis of autism spectrum disorder. Around 30 individuals will be accepted into the trial."
Has the Pimavanserin tartrate molecule been sanctioned by the FDA?
"Our team at Power assessed the safety of Pimavanserin tartrate to be a 2, as Phase 2 trials provide limited evidence regarding its efficacy but some data backing up its safety."
Share this study with friends
Copy Link
Messenger